Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-08-28

Clinical Trial Update: Low-dose Interleukin-2 Treatment on Idiopathic Inflammatory Myopathy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating low-dose interleukin-2 for inflammatory myopathy is in progress, with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Interleukin-2 (interleukin-2)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Inflammatory Myopathy | Phase 2 | Status: UNKNOWN